摘要
目的制备氧化苦参碱(OMT)磷脂复合物(PC)自乳化释药系统(OMT-PC-SEDDS),并对其进行质量评价及体外释放度考察。方法通过伪三元相图的绘制,以乳化区域面积为指标,筛选处方中乳化剂、助乳化剂种类及混合乳化剂比值(K_m),以溶解度大小考察油相种类,确定最佳处方;并对OMT-PC-SEDDS的外观、平均粒径、自乳化时间、体外释放特性及稳定性进行评价。结果 OMT-PC-SEDDS最佳处方为乳化剂Kolliphor HS 15与助乳化剂乙醇质量比为2∶1,中链甘油三酯(MCT)与Kolliphor HS 15和乙醇的总质量的质量比为2∶8。制备得到的OMT-PC-SEDDS外观呈澄明液体,稳定性良好,加水稀释后形成浅乳白色并带淡蓝色乳光的乳液,透射电子显微镜(TEM)观察呈类球形,分布均匀;平均粒径为(355.00±19.50)nm,Zeta电位为(-12.80±0.66)mV。在pH 6.8磷酸缓冲液中,OMT、OMT-PC和OMT-PC-SEDDS的体外释放在4 h分别达到93.84%、88.39%、88.61%。结论考察所得最佳处方制备的OMT-PC-SEDDS粒径适宜,稳定性良好。
Objective To prepare oxymatrine(OMT) phospholipid complex(PC) self-emulsifying drug delivery system(OMT-PCSEDDS), and evaluate its quality and release in vitro. Methods The emulsifiers, co-emulsifiers and ratio of emulsifier to co-emulsifier(Km) were selected through the pseudo-ternary phase diagram method, using emulsified area as selection index, investigation of oil phase by solubility was determined to optimize the prescription. The appearance, average particle diameter, self-emulsification time, in vitro release characteristics, and stability of OMT-PC-SEDDS were evaluated. Results The optimum prescription of OMT-PC-SEDDS was emulsifier Kolliphor HS 15 and co-emulsifier ethanol mass ratio of 2∶1, the mass ratio of medium chain triglyceride(MCT) to the total mass of Kolliphor HS 15 and ethanol was 2∶8. The appearance of OMTPC-SEDDS was translucent clear liquid with good stability. OMT-PC-SEDDS diluted with water to form milky and pale blue emulsion. The emulsion was observed to be spherical by transmission electron microscopy and distributed evenly with average particle size of(355.00 ± 19.50) nm and Zeta potential of(-12.80 ± 0.66) mV. In pH 6.8 phosphate buffer, the in vitro release, the in vitro release of OMT, OMT-PC, and OMT-PC-SEDDS respectively reached 93.84%, 88.39%, and 88.61% at 4 h. Conclusion The prepared OMT-PC-SEDDS by optimum formulation of this study has a good particle size and good stability.
作者
王益
李婉蓉
杨佳佳
周雪
吴林菁
甘诗泉
沈祥春
陶玲
WANG Yi;LI Wan-rong;YANG Jia-jia;ZHOU Xue;WU Lin-jing;GAN Shi-quan;SHEN Xiang-chun;TAO Ling(School of Pharmacy of Guizhou Medical University,Guiyang 550025,China;Key Lab of Optimal Utilization of Natural Medicine Resources,State Key Laboratory of Functions and Applications of Medicinal Plants,Guizhou Key Laboratory of Pharmacology and Druggability for Natural Medicines,GMC-Guiyang City United Laboratory for Natural Medicinal Pharmacology and Drugability,Guizhou Medical University,Guiyang 550014,China)
出处
《中草药》
CAS
CSCD
北大核心
2018年第18期4277-4283,共7页
Chinese Traditional and Herbal Drugs
基金
贵州省高等教育科技创新团队(黔教合人才团队字[2014]31)
贵州省科技创新创新团队(黔科合人才团队[2015]4025号)
贵州省高层次创新型人才百层次人才(贵州科技厅黔科合人才[2015]4029号)
贵州医科大学药学国际科技合作基地(黔科合平台人才[2017]5802)
贵州省科学技术基金重点项目(黔科合JZ字[2015]2002号)
遵义医学院基础药理省部共建教育部重点实验室项目(黔教合KY字[2017]379)
贵阳医学院博士启动基金项目(院博合J字[2017-24]号)
关键词
氧化苦参碱
磷脂复合物
伪三元相图
自乳化释药系统
体外释放
稳定性
oxymatrine
phospholipid complex
pseudo-ternary phase diagram
self-emulsifying drug delivery system
in vitro release
stability